Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Bankim Patel

Internal Medicine Gastonia, NC Medical Doctor

NPI 1801275706 CMS profile 7325590

2711 X Ray Dr Ste 3106, Gastonia, NC 28054

Open in the dashboard

General payments

$3,564

172 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bankim Patel of Gastonia, NC is reported in the CMS Open Payments database as having received $3,564 across 172 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $811 41
2024 General $625 33
2023 General $1,026 43
2022 General $663 33
2021 General $440 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bankim Patel
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Bankim Patel were reported at $811. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Bankim Patel Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $440 $135 $37–$521 $132
2022 $663 $141 $42–$496 $149
2023 $1,026 $149 $45–$519 $160
2024 $625 $154 $47–$537 $164
2025 $811 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $981 74 payments
  2. AbbVie, Inc. $700 32 payments
  3. Abbott Laboratories $349 10 payments
  4. Pfizer Inc. $330 20 payments
  5. Lilly USA, LLC $264 3 payments
  6. Biohaven Pharmaceuticals, Inc. $124 1 payment
  7. Paratek Pharmaceuticals, Inc. $124 1 payment
  8. Janssen Pharmaceuticals, Inc $109 5 payments
  9. Amgen Inc. $100 3 payments
  10. GlaxoSmithKline, LLC. $97 5 payments
  11. Other $386 18 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,564 172 payments
Products named General payments · program years 2021–2025
  1. RYBELSUS $598 45 payments
  2. Ozempic $566 48 payments
  3. UBRELVY $492 20 payments
  4. NURTEC ODT $299 18 payments
  5. FreeStyle Libre 3 $296 7 payments
  6. QULIPTA $269 10 payments
  7. Saxenda $253 17 payments
  8. ZAVZPRET $232 12 payments
  9. Wegovy $199 17 payments
  10. XYOSTED $148 6 payments
  11. Other $1,496 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 121 drugs

Part D claims

6,715

Median for Internal Medicine: 777

Drug cost

$676,640

Median for Internal Medicine: $73,373

Branded share of claims

20.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 126 $149,826
Jardiance Empagliflozin Brand 139 $116,999
Eliquis Apixaban Brand 101 $80,661
Farxiga Dapagliflozin Propanediol Brand 49 $39,868
Rybelsus Semaglutide Brand 24 $38,273
Janumet Sitagliptin Phos/Metformin Hcl Brand 28 $32,799
Trulicity Dulaglutide Brand 29 $32,479
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 37 $29,693
Entresto Sacubitril/Valsartan Brand 23 $21,433
Januvia Sitagliptin Phosphate Brand 21 $20,488

The 10 drugs with the highest cost, of 121 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$52,976

Of which drugs: $6,015

Medicare patients

133

Average age 73

Services billed

914

61 women, 72 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 42%
Diabetes 40%
Chronic kidney disease 35%
Ischemic heart disease 25%
Heart failure 23%
Atrial fibrillation 22%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 16 16 $4,637
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 42 42 $920
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 15 29 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $95
$95 — —
XYOSTED
  • Antares Pharma, Inc. $69
$69 — —
RYBELSUS
  • Novo Nordisk Inc $51
$51 24 —
Ozempic
  • Novo Nordisk Inc $51
$51 126 —
NURTEC ODT
  • PFIZER INC. $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

172 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record